Electra Therapeutics, Inc. (ETRA) Income Statement

NASDAQ: ETRARevenue, profits, margins and EPS over 2 years.

ETRA 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Research & development+161.5%
$50.4M
2025 · hover or tap a bar for each year
2024: $19.3M2025: $50.4M (+161.5%)
20242025
Operating expenses+135.2%
$61.9M
2025 · hover or tap a bar for each year
2024: $26.3M2025: $61.9M (+135.2%)
20242025
Operating income
−$61.9M
2025 · hover or tap a bar for each year
2024: −$26.3M2025: −$61.9M
20242025
Net income
−$62.0M
2025 · hover or tap a bar for each year
2024: −$24.8M2025: −$62.0M
20242025
EPS (diluted)
−$0.99
2025 · hover or tap a bar for each year
2025: −$0.99
20242025

ETRA revenue and net income

RevenueNet incomeNet margin (right axis)

ETRA growth rates

to 2025
1 year3 years5 years10 years
Revenue————
Operating income————
Net income————
EPS (diluted)————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

ETRA income statement

Electra Therapeutics, Inc. annual income statement
20252024
Revenue$0$0
Research & development$50.4M$19.3M
Sales, general & admin$11.5M$7.0M
Total operating expenses$61.9M$26.3M
Operating income−$61.9M−$26.3M
Interest income$1.4M$1.5M
Interest expense$1.4M$0
Income before taxes−$62.0M−$24.8M
Net income−$62.0M−$24.8M
EBITDA−$60.5M−$24.8M
EPS (diluted)−$0.99—

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ETRA's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.

ETRA financial results

Electra Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $62.0 million. Diluted earnings per share came to −$0.99.

See the ETRA stock overview for the latest quote and news, or the ETRA chart for price history and technical indicators.

ETRA income statement FAQ

Does Electra Therapeutics have revenue?

Electra Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.

Is Electra Therapeutics profitable?

No. Electra Therapeutics reported a net loss of $62.0 million in fiscal 2025.

How much does Electra Therapeutics spend on research and development?

Electra Therapeutics spent $50.4 million on research and development in fiscal 2025.

What are Electra Therapeutics's earnings per share?

Electra Therapeutics earned $-0.99 per diluted share in fiscal 2025.

When does Electra Therapeutics's fiscal year end?

Electra Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.

Biotechnology income statements